SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma gains on reporting 16% rise in Q3 consolidated net profit

01 Feb 2026 Evaluate

Sun Pharmaceutical Industries is currently trading at Rs. 1613.00, up by 18.00 points or 1.13% from its previous closing of Rs. 1595.00 on the BSE.

The scrip opened at Rs. 1652.65 and has touched a high and low of Rs. 1655.80 and Rs. 1590.10 respectively. So far 129874 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1850.95 on 02-May-2025 and a 52 week low of Rs. 1547.25 on 26-Sep-2025.

Last one week high and low of the scrip stood at Rs. 1673.80 and Rs. 1583.60 respectively. The current market cap of the company is Rs. 386196.96 crore.

The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 36.93% and 8.58% respectively.

Sun Pharmaceutical Industries has reported 38.97% fall in its net profit at Rs 705.44 crore for the third quarter ended December 31, 2025 as compared to Rs 1,155.80 crore for the same quarter in the previous year. The total income of the company decreased by 6.11% at Rs 5,867.67 crore for Q3FY26 as compared to Rs 6,249.83 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported 16.03% rise in its net profit at Rs 3,368.81 crore for the third quarter ended December 31, 2025 as compared to Rs 2,903.38 crore for the same quarter in the previous year. The total income of the company increased by 13.85% at Rs 16,099.38 crore for Q3FY26 as compared to Rs 14,141.08 crore for the corresponding quarter previous year.



Sun Pharma Inds. Share Price

1675.20 -17.95 (-1.06%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×